Floy GmbH

Name: Floy GmbH
Brand: Floy

AI Native

Maximizing the diagnostic value of routine imaging with artificial intelligence.

Est 2021|Raised $12.8M

LinkedIn 20K|Web traffic 5K|FTEs 65|HQ Munich, Bavaria, DE

Published Jul 14, 2026

01Common complaints

1) Organizations that require abundant, independently verified peer reviews and referenceable ROI case studies prior to procurement. - Floy’s public footprint on major review platforms is limited, making independent validation more challenging. 2) US health systems that require FDA-cleared modules for immediate deployment. - Floy’s public materials focus on the EU/German market; confirm US regulatory status before pursuing production deployment in the US. 3) Organizations that require fully transparent, publicly documented enterprise security controls before vendor engagement. - Floy provides patient privacy information and references encryption, but detailed enterprise security documentation (SOC 2, ISO 27001, data residency specifics) is not publicly documented in accessible materials. 4) Organizations that lack governance or capacity to manage increased incidental findings follow-up. - Opportunistic screening increases downstream work; if a site cannot absorb additional follow-up or patient communication tasks, net benefit may be reduced. 5) Use cases that prioritize acute triage (e.g., stroke, PE, ICH) with comprehensive workflow orchestration. - Vendors with triage-first platforms and broad hospital experience may be better suited for acute triage workflows.

Disqualifiers (poor fit signals)

Organizations that require publicly documented SOC 2 / ISO 27001 evidence before engagement
Sites unable to operationalize incidental findings follow-up pathways
Use cases outside the vendor’s certified module scope

Publicly observable limitations (from research)

Limited independent customer review density, reducing externally verifiable satisfaction and performance data.
Gaps in publicly documented enterprise security/compliance evidence (SOC 2 / ISO 27001 not found in accessible sources).
Ambiguity around module scope and certification: vendor statements suggest module-level certification and third-party licensor involvement; buyers must validate intended use and certification status for each module.

Roadmap / upcoming modules (vendor signals)

Company communications reference planned modules (e.g., knee and shoulder products) but public timelines and regulatory status for these products are not provided.

02Why they buy

Distinctive aspects supported by accessible evidence

Commercial model: Press coverage and company profiles describe a patient self-pay add-on and revenue-sharing approach with practices, which is a notable go-to-market characteristic.
Opportunistic screening focus: Floy emphasizes extracting additional risk signals from routine imaging (bone health, vascular indicators, incidental findings).
Reported regional adoption: Multiple public sources and company communications report substantial adoption in Germany.

Where competitors may have clearer advantages

Larger competitors may offer:

Broader independent validations and reference installations
More established international regulatory clearances and enterprise security/compliance documentation
Deeper hospital integration and orchestration experience

03Field reports

What’s available publicly

Floy is a specialized vendor with limited public review coverage on major software review platforms. #### Review platforms - G2: Floy has a vendor page that shows little to no reviews, providing insufficient quantitative feedback. - Gartner Peer Insights: Limited or no accessible product review corpus for Floy was identified in the sources reviewed. - TrustRadius / Capterra / PeerSpot: Few clear Floy product review pages were located; searches were often confounded by similarly named products. #### Community / social discussion Public discussions specific to Floy are limited in accessible search results; available threads tend to address the broader topic of AI in radiology rather than this vendor specifically.

Vendor-published testimonials (context)

Vendor materials include clinician statements asserting added value and increased detection or safety when using the product. These vendor-published testimonials illustrate the vendor’s positioning but are marketing-selected and should not be treated as representative satisfaction data without independent verification.

Third-party partner references (adjacent evidence)

Some partner radiology practices publish informational pages describing their use of Floy for additional AI analysis. These materials describe integrating Floy outputs into reporting workflows and framing the product as an additional review layer.

Caution: partner pages are not independent review platforms and may reflect co-marketing relationships.

Employee sentiment (operational proxy)

Employer review sites provide an indirect signal about operational risks: - kununu (German employer reviews): Floy shows a mid-range score with comments referencing both positive aspects (interesting work, autonomy) and criticisms (compensation, workloads). - Glassdoor: a company reviews page exists with limited accessible content. Why this matters to buyers: rapid growth at medtech startups can correlate with scaling challenges (support capacity, implementation consistency). Employee review sites are a weak signal but can indicate potential delivery risk.

What’s publicly available

Floy’s site and press releases include partner references and high-level outcome statements, but detailed, independently validated case studies (with clear methodology, baseline comparisons, and measured operational impact) are limited in accessible public sources.

Examples of vendor-stated metrics (context)

Vendor pages reference literature-based claims about earlier detection and test performance characteristics (sensitivity/false-positive profiles) for select tasks. These references often point to study-level evidence rather than transparent, named-site production deployments. Critical evaluation: - Available materials appear to mix literature citations with vendor-assembled outcomes; methodology details (patient mix, disease prevalence, reading protocols, ground-truth definitions, and the impact of reader behavior changes) are often not disclosed.

What to request from Floy

For credible procurement evaluation, request:

Named reference sites with permission to contact
Pre/post deployment metrics: report turnaround time, recall rates, follow-up costs, and detection yield
Details on drift monitoring, update cadence, and model versioning policy
Quantification of false-positive workup burden (radiologist time per case)

04Best fit

Company sizes

Best-fit profile based on public positioning and rollout claims:

Ambulatory radiology practices and multi-site radiology networks (roughly small to mid-sized groups); networked practices may gain more from standardized AI add-on services.

Industries / verticals

Outpatient imaging centers
Radiology networks
Preventive medicine and screening-oriented practices that may offer patient-paid service add-ons

Roles/personas

Decision makers: practice owners, medical directors, radiology network leadership, operations leadership
Technical buyers: PACS/RIS administrators, IT/security leads
End users: radiologists, technologists (indirect), reporting staff

Best-fit pain points

High reading volumes and demand growth
Interest in monetizing preventive insights or offering differentiating patient services
Need for standardized quantification and longitudinal comparisons

05The pitch

What the product does (objective value proposition)

Floy GmbH develops AI-assisted radiology software that functions as a secondary review capability to analyze routine radiology studies (e.g., CT/MRI, and mammography) to surface additional findings and quantitative measurements that may be overlooked in standard reads. Floy positions the product for two main use areas: - Opportunistic screening (e.g., osteoporosis/bone health, vascular/cardiovascular risk signals, incidental findings), and - Diagnostic assistance (quantification/measurements, follow-up comparison, and targeted detection support in selected clinical domains). On its website, Floy describes the tool as extending radiology reports to include findings beyond the primary clinical focus and provides a consolidated report output labeled the "FloyReport".

Target market and positioning

Floy primarily targets: - Ambulatory radiology practices and radiology networks in Germany with planned broader European rollout, and - In some messaging, patients via a supplementary self-pay model attached to standard radiology appointments (a "second look" service), with revenue-share arrangements between Floy and partner practices (reported in press coverage). This approach differs from vendors that focus primarily on hospital enterprise licensing or per-algorithm sales; Floy emphasizes a commercial model intended to fit outpatient practice economics.

Get a comprehensive analysis of Floy GmbH including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Jul 14, 2026

01Common complaints

Organizations that require abundant, independently verified peer reviews and referenceable ROI case studies prior to procurement.
- Floy’s public footprint on major review platforms is limited, making independent validation more challenging.
US health systems that require FDA-cleared modules for immediate deployment.
- Floy’s public materials focus on the EU/German market; confirm US regulatory status before pursuing production deployment in the US.
Organizations that require fully transparent, publicly documented enterprise security controls before vendor engagement.
- Floy provides patient privacy information and references encryption, but detailed enterprise security documentation (SOC 2, ISO 27001, data residency specifics) is not publicly documented in accessible materials.
Organizations that lack governance or capacity to manage increased incidental findings follow-up.
- Opportunistic screening increases downstream work; if a site cannot absorb additional follow-up or patient communication tasks, net benefit may be reduced.
Use cases that prioritize acute triage (e.g., stroke, PE, ICH) with comprehensive workflow orchestration.
- Vendors with triage-first platforms and broad hospital experience may be better suited for acute triage workflows.

Disqualifiers (poor fit signals)

Organizations that require publicly documented SOC 2 / ISO 27001 evidence before engagement
Sites unable to operationalize incidental findings follow-up pathways
Use cases outside the vendor’s certified module scope

Publicly observable limitations (from research)

Limited independent customer review density, reducing externally verifiable satisfaction and performance data.
Gaps in publicly documented enterprise security/compliance evidence (SOC 2 / ISO 27001 not found in accessible sources).
Ambiguity around module scope and certification: vendor statements suggest module-level certification and third-party licensor involvement; buyers must validate intended use and certification status for each module.

Roadmap / upcoming modules (vendor signals)

Company communications reference planned modules (e.g., knee and shoulder products) but public timelines and regulatory status for these products are not provided.

02Why they buy

Distinctive aspects supported by accessible evidence

Commercial model: Press coverage and company profiles describe a patient self-pay add-on and revenue-sharing approach with practices, which is a notable go-to-market characteristic.
Opportunistic screening focus: Floy emphasizes extracting additional risk signals from routine imaging (bone health, vascular indicators, incidental findings).
Reported regional adoption: Multiple public sources and company communications report substantial adoption in Germany.

Where competitors may have clearer advantages

Larger competitors may offer:

Broader independent validations and reference installations
More established international regulatory clearances and enterprise security/compliance documentation
Deeper hospital integration and orchestration experience

03Field reports

What’s available publicly

Floy is a specialized vendor with limited public review coverage on major software review platforms.

Review platforms

G2: Floy has a vendor page that shows little to no reviews, providing insufficient quantitative feedback.
Gartner Peer Insights: Limited or no accessible product review corpus for Floy was identified in the sources reviewed.
TrustRadius / Capterra / PeerSpot: Few clear Floy product review pages were located; searches were often confounded by similarly named products.

Community / social discussion

Public discussions specific to Floy are limited in accessible search results; available threads tend to address the broader topic of AI in radiology rather than this vendor specifically.

Vendor-published testimonials (context)

Third-party partner references (adjacent evidence)

Caution: partner pages are not independent review platforms and may reflect co-marketing relationships.

Employee sentiment (operational proxy)

Employer review sites provide an indirect signal about operational risks:

kununu (German employer reviews): Floy shows a mid-range score with comments referencing both positive aspects (interesting work, autonomy) and criticisms (compensation, workloads).
Glassdoor: a company reviews page exists with limited accessible content.

Why this matters to buyers: rapid growth at medtech startups can correlate with scaling challenges (support capacity, implementation consistency). Employee review sites are a weak signal but can indicate potential delivery risk.

What’s publicly available

Examples of vendor-stated metrics (context)

Critical evaluation:

Available materials appear to mix literature citations with vendor-assembled outcomes; methodology details (patient mix, disease prevalence, reading protocols, ground-truth definitions, and the impact of reader behavior changes) are often not disclosed.

What to request from Floy

For credible procurement evaluation, request:

Named reference sites with permission to contact
Pre/post deployment metrics: report turnaround time, recall rates, follow-up costs, and detection yield
Details on drift monitoring, update cadence, and model versioning policy
Quantification of false-positive workup burden (radiologist time per case)

04Best fit

Company sizes

Best-fit profile based on public positioning and rollout claims:

Ambulatory radiology practices and multi-site radiology networks (roughly small to mid-sized groups); networked practices may gain more from standardized AI add-on services.

Industries / verticals

Outpatient imaging centers
Radiology networks
Preventive medicine and screening-oriented practices that may offer patient-paid service add-ons

Roles/personas

Decision makers: practice owners, medical directors, radiology network leadership, operations leadership
Technical buyers: PACS/RIS administrators, IT/security leads
End users: radiologists, technologists (indirect), reporting staff

Best-fit pain points

High reading volumes and demand growth
Interest in monetizing preventive insights or offering differentiating patient services
Need for standardized quantification and longitudinal comparisons

05The pitch

What the product does (objective value proposition)

Opportunistic screening (e.g., osteoporosis/bone health, vascular/cardiovascular risk signals, incidental findings), and
Diagnostic assistance (quantification/measurements, follow-up comparison, and targeted detection support in selected clinical domains).

On its website, Floy describes the tool as extending radiology reports to include findings beyond the primary clinical focus and provides a consolidated report output labeled the "FloyReport".

Target market and positioning

Floy primarily targets:

Ambulatory radiology practices and radiology networks in Germany with planned broader European rollout, and
In some messaging, patients via a supplementary self-pay model attached to standard radiology appointments (a "second look" service), with revenue-share arrangements between Floy and partner practices (reported in press coverage).

This approach differs from vendors that focus primarily on hospital enterprise licensing or per-algorithm sales; Floy emphasizes a commercial model intended to fit outpatient practice economics.

Get a comprehensive analysis of Floy GmbH including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →